Tiller 1999.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM‐III‐R panic disorder Method of diagnosis: Structured Clinical Interview (SCID) Age: M = 35 Sex: 67% female Location: not stated; setting: unclear Co‐morbidities: not stated Rescue medication: not stated; "there was not extensive co‐prescription of hypnotics, sedatives or beta‐blockers".
Interventions	Participants were randomly assigned to either: (1) moclobemide arm (n = 182) Duration: 8 weeks Treatment Protocol: flexible dosage, range = 300 ‐ 600 mg, M = 498, SD = 68 (2) fluoxetine arm (n = 184) Duration: 8 weeks Treatment Protocol: flexible dosage, range = 10 ‐ 30 mg, M = 20.5, SD = 2.7
Outcomes	Time points for assessment: Outcomes: 1. number of adverse events 2. severe adverse events 3. clinical global impression of tolerability 4. panic‐free patients 5. Clinical Global Impression Scale (CGI)
Notes	Date of study: not stated Funding source: sponsored by Hoffmann‐La Roche Declarations of interest among the primary researchers: none.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomly allocated"
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double blind". No further information provided.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double blind". No further information provided.
Incomplete outcome data (attrition bias) All outcomes	High risk	No information provided about management of incomplete outcome data; number of total dropouts not reported.
Selective reporting (reporting bias)	Unclear risk	All relevant outcomes mentioned in the methods section were reported.
Other bias	High risk	Sponsored by Hoffmann‐La Roche; the role of the funder in planning, conducting and writing the study is not discussed.